Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Abuse
Conditions
Drug Abuse, Healthy
Trial Timeline
Dec 1, 2008 โ Apr 1, 2009
NCT ID
NCT00828659About Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3
Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3 is a phase 1 stage product being developed by Eisai for Drug Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT00828659. Target conditions include Drug Abuse, Healthy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00828659 | Phase 1 | Completed |
Competing Products
20 competing products in Drug Abuse